IGC Pharma (IGC) Non-Current Deferred Tax Liability (2011 - 2012)
IGC Pharma (IGC) reported Non-Current Deferred Tax Liability of $713897.0 for Q4 2012, little changed year-over-year from $713897.0 in Q1 2012, and little changed quarter-over-quarter from $713897.0 in Q3 2012.
IGC Pharma (IGC) Non-Current Deferred Tax Liability (2011 - 2012) Analysis & Trends
IGC Pharma (IGC) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $713897.0 in Q4 2012.
- Non-Current Deferred Tax Liability for Q4 2012 came in at $713897.0, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2012 was $713897.0 (changed 0.0% YoY), and the FY2012 annual result was $713897.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability steadied at $713897.0 in Q4 2012 per IGC's latest filing, from $713897.0 in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $713897.0 in Q4 2011 and troughed at $713897.0 in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | IGC Pharma | 28.11 Mn | 27.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 713,897.00 |
| Dec 31, 2012 | 713,897.00 |
| Sep 30, 2012 | 713,897.00 |
| Sep 30, 2012 | 713,897.00 |
| Jun 30, 2012 | 713,897.00 |
| Jun 30, 2012 | 713,897.00 |
| Mar 31, 2012 | 713,897.00 |
| Mar 31, 2012 | 713,897.00 |
| Dec 31, 2011 | 713,897.00 |
| Dec 31, 2011 | 713,897.00 |